Nektar Therapeutics <NKTR.O>: Canaccord Genuity initiates coverage with Buy rating; target price $153
NKTR•Related News
GE Vernova, Arrowhead Pharma
SPY•
Nasdaq trade halt continues <PLTS.O> reason not available at 10:05 AM
PLTS•
CME Group beats profit estimates as hedging demand lifts equity volumes
CME•
Data guzzler threatens software’s last moat
XLK•
Paylocity Holding Corp <PCTY.O>: UBS Raises Target Price To $128 From $122
PCTY•